OneMedNet 2025 Q1 Earnings Net Loss Improves by 9.8%
Daily EarningsWednesday, May 14, 2025 11:26 pm ET
3min readOneMedNet(ONMD) reported its fiscal 2025 Q1 earnings on May 14th, 2025. The company experienced a significant revenue decline, missing expectations with a 44.8% year-over-year decrease to $137,000 in Q1 2025. Despite this, narrowed its losses, reporting an improved net loss compared to the previous year. Looking forward, the company maintains its guidance, projecting gradual revenue recovery with a target of $1 million for 2025. Investments in technology and partnerships are expected to drive growth as market conditions improve.
Revenue
The total revenue of OneMedNet decreased by 44.8% to $137,000 in 2025 Q1, down from $248,000 in 2024 Q1.
Earnings/Net Income
OneMedNet narrowed losses to $0.06 per share in 2025 Q1 from a loss of $0.08 per share in 2024 Q1 (25.0% improvement). Meanwhile, the company successfully narrowed its net loss to $-1.90 million in 2025 Q1, reducing losses by 9.8% compared to the $-2.11 million net loss reported in 2024 Q1. The Company has sustained losses for 3 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. Despite the revenue drop, the improved EPS indicates better financial management.
Price Action
The stock price of OneMedNet has surged 15.16% during the latest trading day, has surged 20.31% during the most recent full trading week, and has climbed 4.00% month-to-date.
Post-Earnings Price Action Review
The strategy of buying OneMedNet (ONMD) shares after their revenue drop on the financial report release date and holding for 30 days has historically resulted in a loss of 2.10%. This suggests that the strategy has not been profitable for over the past five years, with a 5-year annualized return of -2.10%, indicating a decline in value. If an investor had bought $100 of ONMD stock on the release date of the financial report five years ago, it would be worth $97.90 today, based on the current stock price of $445.97. Despite short-term price surges, the long-term strategy reveals persistent challenges in achieving profitable returns.
CEO Commentary
Aaron Green, CEO of OneMedNet, highlighted the company’s continued focus on enhancing its digital imaging solutions despite facing revenue challenges, noting a 44.76% decline in revenue year-over-year to $137,000. He acknowledged the strategic priority of refining operational efficiencies and optimizing costs, which contributed to a reduction in net loss to $1.902 million, down 9.82% from the previous year. Green expressed cautious optimism, emphasizing that the market's evolving needs present opportunities for growth and that OneMedNet remains committed to leveraging real-world data to enhance clinical outcomes.
Guidance
For the upcoming quarters, OneMedNet expects to maintain a strategic focus on revenue growth, projecting a gradual recovery as market conditions improve. The company aims to achieve a revenue target of approximately $1 million for 2025, with an anticipated EPS of -$0.20. Green indicated that investments in technology and partnerships will be pivotal in driving this growth, as they enhance the company's market positioning and operational capabilities.
Additional News
In recent weeks, OneMedNet has announced significant advancements in data collaboration. The company has integrated its imaging Real-World Data (iRWD) into the HealthVerity Marketplace, expanding access for life sciences research. Additionally, OneMedNet partnered with Protege to enhance AI-driven healthcare with real-time, multimodal data access, furthering its capabilities in AI model development. These strategic partnerships underscore OneMedNet's commitment to leveraging its extensive healthcare datasets for improved research and development outcomes. Furthermore, Dr. Kenneth Alleyne joined the Board of Directors, bringing valuable expertise in healthcare and corporate governance to strengthen the company's strategic initiatives.
Revenue
The total revenue of OneMedNet decreased by 44.8% to $137,000 in 2025 Q1, down from $248,000 in 2024 Q1.
Earnings/Net Income
OneMedNet narrowed losses to $0.06 per share in 2025 Q1 from a loss of $0.08 per share in 2024 Q1 (25.0% improvement). Meanwhile, the company successfully narrowed its net loss to $-1.90 million in 2025 Q1, reducing losses by 9.8% compared to the $-2.11 million net loss reported in 2024 Q1. The Company has sustained losses for 3 years over the corresponding fiscal quarter, highlighting ongoing financial headwinds. Despite the revenue drop, the improved EPS indicates better financial management.
Price Action
The stock price of OneMedNet has surged 15.16% during the latest trading day, has surged 20.31% during the most recent full trading week, and has climbed 4.00% month-to-date.
Post-Earnings Price Action Review
The strategy of buying OneMedNet (ONMD) shares after their revenue drop on the financial report release date and holding for 30 days has historically resulted in a loss of 2.10%. This suggests that the strategy has not been profitable for over the past five years, with a 5-year annualized return of -2.10%, indicating a decline in value. If an investor had bought $100 of ONMD stock on the release date of the financial report five years ago, it would be worth $97.90 today, based on the current stock price of $445.97. Despite short-term price surges, the long-term strategy reveals persistent challenges in achieving profitable returns.
CEO Commentary
Aaron Green, CEO of OneMedNet, highlighted the company’s continued focus on enhancing its digital imaging solutions despite facing revenue challenges, noting a 44.76% decline in revenue year-over-year to $137,000. He acknowledged the strategic priority of refining operational efficiencies and optimizing costs, which contributed to a reduction in net loss to $1.902 million, down 9.82% from the previous year. Green expressed cautious optimism, emphasizing that the market's evolving needs present opportunities for growth and that OneMedNet remains committed to leveraging real-world data to enhance clinical outcomes.
Guidance
For the upcoming quarters, OneMedNet expects to maintain a strategic focus on revenue growth, projecting a gradual recovery as market conditions improve. The company aims to achieve a revenue target of approximately $1 million for 2025, with an anticipated EPS of -$0.20. Green indicated that investments in technology and partnerships will be pivotal in driving this growth, as they enhance the company's market positioning and operational capabilities.
Additional News
In recent weeks, OneMedNet has announced significant advancements in data collaboration. The company has integrated its imaging Real-World Data (iRWD) into the HealthVerity Marketplace, expanding access for life sciences research. Additionally, OneMedNet partnered with Protege to enhance AI-driven healthcare with real-time, multimodal data access, furthering its capabilities in AI model development. These strategic partnerships underscore OneMedNet's commitment to leveraging its extensive healthcare datasets for improved research and development outcomes. Furthermore, Dr. Kenneth Alleyne joined the Board of Directors, bringing valuable expertise in healthcare and corporate governance to strengthen the company's strategic initiatives.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet